GLP-1 and GIP Receptor Agonists for Diabetes and Obesity Emerge as Multitarget Therapies for Spinal Cord Injury
Background
Spinal cord injury (SCI) is a devastating neurological condition that profoundly undermines a patient's independent life. Globally, thousands of individuals are affected annually, yet no treatment currently exists to fully restore damaged spinal cord neurons due to the complex pathophysiology of the disease. Following the initial mechanical trauma, which causes direct neuronal death, secondary injury occurs over months due to microenvironmental imbalances, leading to cell death and inflammation.
Current clinical interventions, such as early decompression and high-dose glucocorticoid administration, have clear limitations. These approaches target only single pathways, resulting in suboptimal efficacy and side effects such as immunosuppression. Therefore, a paradigm shift toward a multitarget strategy that comprehensively corrects the abnormal microenvironment at the injury site is necessary.
Recently, the incretin hormone system, which has emerged as a game-changer in diabetes and obesity treatment, offers a promising alternative. Incretins are hormones secreted by the gut after meals, promoting insulin secretion and glucose regulation. The academic community is increasingly focusing on the neuroprotective properties of key incretins, particularly glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
Key Findings
Incretin receptor agonists not only regulate blood glucose but also exert direct effects on the central nervous system, offering diverse neuroprotective benefits. Preclinical studies have demonstrated that these drugs strongly suppress the inflammatory response following SCI. Specifically, they induce microglia and macrophages at the injury site to adopt anti-inflammatory phenotypes, thereby reducing the secretion of toxic inflammatory mediators.
Additionally, these agents promote neuronal survival by inhibiting apoptosis and enhancing autophagy, which clears cellular waste. They also stimulate axonal regeneration and alleviate oxidative stress, fundamentally improving the regenerative microenvironment at the injury site.
Dual agonists that simultaneously activate both GLP-1 and GIP receptors have shown superior therapeutic efficacy compared to single agents. This enhanced effect is attributed to the synergistic action of the two hormonal pathways, which suppresses neural damage and stabilizes intracellular metabolism. These neuroprotective mechanisms, previously validated in models of other neurodegenerative diseases, have now been shown to be effective in SCI as well.
Implications and Outlook
This research provides a scientific foundation for repurposing incretin-based drugs, which have already demonstrated safety in diabetes and obesity treatment, as potential therapies for SCI. Drug repurposing using already validated medications offers a shortcut to significantly reduce the time and cost of developing new drugs. The added benefit of managing metabolic complications commonly associated with SCI is also a positive factor.
However, several challenges remain before these drugs can be adopted in clinical practice. It is necessary to confirm whether the effects observed in preclinical models are reproducible in humans. Additional validation using large animal models such as primates or pigs is essential beyond rodent-based studies.
Research into formulation technologies to improve drug delivery efficiency is also a critical task. Effective delivery systems, such as nanoparticles, must be developed to enable the drugs to cross the blood-brain barrier (BBB) and reach the injured spinal cord. Only with a systematic design of clinical trials can these drugs become viable treatment options for patients.
Spinal cord injury (SCI) constitutes a major global health challenge. The pathophysiology of SCI involves many aspects. Current treatments, such as early decompression and glucocorticoids, target single pathways and show limited efficacy with safety concerns. In this context, interventions based on the incretin system are now considered attractive candidates for SCI intervention. This review comprehensively outlines the mechanisms underlying microenvironmental imbalance following SCI and explores glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists as promising options. These agents, recognized for their role in managing diabetes and body weight, demonstrate substantial pleiotropic effects beyond simple glycemic regulation. These beneficial actions include neuroprotection, anti-inflammatory effects, and the promotion of tissue repair. Preclinical SCI studies have indicated that GLP-1 receptor agonists and GIP receptor agonists reduce inflammation by shifting microglia/macrophages to anti-inflammatory phenotypes, suppress apoptosis, increase autophagy, alleviate oxidative stress, promote axonal regeneration, improve the injury microenvironment, and have the potential to regulate immune cells. Related research in other neurological disorders supports these mechanisms, with dual agonists showing superior efficacy. GLP-1 receptor agonists and GIP receptor agonists suggest significant potential to address the multifaceted pathology and associated metabolic complications of SCI. Current evidence highlights the importance of mechanistic elucidation, dose optimization, the development of innovative delivery systems such as nanoparticles, and further validation in large animal and human studies.
This research presents a concrete application scenario that could shift the paradigm of SCI treatment. In clinical settings, GLP-1 and GIP dual agonists could be rapidly administered via injection during the golden time immediately following injury to minimize secondary neural damage. For example, these drugs could be used in emergency rescue or early intensive care unit admission to prevent large-scale neuronal death and inflammation. Furthermore, for chronic SCI patients in the rehabilitation phase, continuous administration of these drugs could enhance neural regeneration and improve motor function. From a pharmaceutical industry perspective, expanding the indications of existing obesity and diabetes drugs to SCI could reduce development risks. A strategic approach would involve capturing the high-unmet medical need in the rare disease market to secure exclusive value.